Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more
Cellectis SA - Asset Resilience Ratio
Cellectis SA (CLLS) has an Asset Resilience Ratio of 40.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Cellectis SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cellectis SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $137.98 Million | 40.22% |
| Total Liquid Assets | $137.98 Million | 40.22% |
Asset Resilience Insights
- Very High Liquidity: Cellectis SA maintains exceptional liquid asset reserves at 40.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cellectis SA Industry Peers by Asset Resilience Ratio
Compare Cellectis SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Cellectis SA (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Cellectis SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.52% | $117.06 Million | $383.54 Million | +10.44pp |
| 2023-12-31 | 20.08% | $67.11 Million | $334.27 Million | +17.05pp |
| 2022-12-31 | 3.03% | $7.91 Million | $261.22 Million | +2.90pp |
| 2021-12-31 | 0.13% | $499.00K | $382.08 Million | -5.64pp |
| 2020-12-31 | 5.77% | $27.09 Million | $469.47 Million | +1.41pp |
| 2019-12-31 | 4.36% | $20.39 Million | $467.47 Million | +4.28pp |
| 2018-12-31 | 0.08% | $388.00K | $500.84 Million | -12.12pp |
| 2017-12-31 | 12.20% | $40.60 Million | $332.88 Million | +1.16pp |
| 2016-12-31 | 11.04% | $36.51 Million | $330.68 Million | +10.57pp |
| 2014-12-31 | 0.47% | $787.00K | $167.34 Million | -- |